USD $2760.00
Products matching the full generic name: Osimertinib
Tagrisso (Osimertinib) 80mg is a medication prescribed for the treatment of non-small cell lung cancer (NSCLC). It is specifically used in cases where the cancer has a mutation in the epidermal growth factor receptor (EGFR). As a third-generation EGFR tyrosine kinase inhibitor (TKI), Tagrisso works by targeting and inhibiting the mutated forms of the EGFR, thereby reducing the growth and spread of cancer cells.
Tagrisso operates by selectively binding to and inhibiting the activity of the EGFR with specific mutations that contribute to the proliferation of cancer cells. By blocking these signals, Tagrisso helps slow down or stop the growth of these cancerous cells, which can lead to a reduction in tumor size and delay the progression of the disease.
Tagrisso is intended for patients diagnosed with non-small cell lung cancer that tests positive for EGFR mutations. It is often prescribed for patients whose cancer has progressed despite previous EGFR TKI therapy or as a first-line treatment in certain cases. It is crucial to have a healthcare professional confirm the presence of EGFR mutations before starting treatment with Tagrisso.
The usual recommended dosage of Tagrisso is one 80mg tablet taken orally once daily. It can be taken with or without food. Patients should follow their healthcare provider's instructions and not alter the dosage unless advised. Consistency in taking the medication at the same time each day is recommended for optimal results.
Common side effects of Tagrisso may include diarrhea, rash, dry skin, and nail problems. Some patients might experience more severe side effects such as lung problems, heart issues, or eye disorders. It is important to contact a healthcare professional if any severe or persistent side effects occur.
Tagrisso should be stored at room temperature, away from moisture and direct light. Keep the medication in its original packaging and ensure it is out of reach of children and pets. Do not use this medication after the expiration date indicated on the packaging.
It is essential to inform your healthcare provider about all medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Some medications may interact with Tagrisso, potentially altering its effectiveness or increasing the risk of adverse effects.
For more detailed information about Tagrisso, including clinical studies and patient support resources, please consult your healthcare provider or refer to the official prescribing information provided by the manufacturer.
Health Guides